The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
Status unconfirmed · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
Key facts
- Study ID
- NCT04768868
- Run by
- Impact Therapeutics, Inc.
- People needed
- 350
- Starts
- 2021-02-25
- Expected to finish
- 2023-08-30
- Last updated by the study team
- 2023-02-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Taiwan University Hospital — Taipei, Taiwan (enrolling)
- University of Kansas Clinical Research Center — Fairway, Kansas, United States (enrolling)
- Norton Cancer Institute — Louisville, Kentucky, United States (enrolling)
- Chi Mei Hospital, Liouying — Tainan, Taiwan (enrolling)
- Emory University Hospital — Atlanta, Georgia, United States (enrolling)
- Mary Crowley Cancer Research — Dallas, Texas, United States (enrolling)
- Next Oncology — San Antonio, Texas, United States (enrolling)
- Wuhan Union Hospital — Wuhan, HB, China (enrolling)
- West China 2nd University Hospital — Chengdu, Sichuan, China (enrolling)
- Beijing Cancer Hospital — Beijing, China (enrolling)
- Fudan University Shanghai Cancer Center — Shanghai, China (enrolling)
- Chang Gung Medical Foundation - Linkou Branch — Taoyuan, TW, Taiwan (enrolling)
- China Medical University Hospital — Taichung, Taiwan (enrolling)
- National Cheng Kung University Hospital — Tainan, Taiwan (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.